Literature DB >> 32034995

The utility of elastography during EBUS-TBNA in a population with a high prevalence of anthracosis.

Atefeh Abedini1, Fatemeh Razavi1, Mehrdad Farahani2, Marzieh Hashemi1, Habib Emami3, Forouzan Mohammadi4, Arda Kiani5.   

Abstract

BACKGROUND: Ultrasound elastography, is a pioneer sonographic modality that is conducted during endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in order to increase the accuracy of sampling location. The current study aims to evaluate the usefulness of elastography during EBUS-TBNA in a population with a high prevalence of anthracosis.
METHODS: This prospective single-blinded study was performed on 69 lymph nodes (LNs) of patients with mediastinal lymphadenopathy undergoing EBUS-TBNA and EBUS-elastography from October 2017 to July 2018. The stiffness level of the tissue was translated into a color to demonstrate the hardness of tissue. Blue and total areas of each section were measured to calculate the hardness of each LN.
RESULTS: Sixty-nine LNs were evaluated by elastography. Twenty percent of LNs were malignant. There was a statistical difference between malignant and non-malignant nodes based on color dominancy (P = 0.032). However, with the exclusion of anthracosis nodes from the analysis, the difference was more significant (P < 0.001). Moreover, when the blue dominancy was used as the predictor of malignancy or anthracosis, the results showed a significant correlation (P < 001).
CONCLUSION: The usefulness of elastography in selecting the hardest area of tissue that is appropriate for diagnosing diseases has been proven previously. Since in countries with a high prevalence of anthracosis, blue color achieved using elastography predicts either malignancy or anthracosis so, cases with blue dominancy of LNs in elastography and the white color in the EBUS-TBNA indicate anthracosis-caused calcification should be reconsidered.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  EBUS-TBNA; anthracosis(D055008); elastography(D054459)

Mesh:

Year:  2020        PMID: 32034995     DOI: 10.1111/crj.13159

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  6 in total

1.  Influential Factors for Assessing Endobronchial Ultrasound Elastography.

Authors:  Keigo Uchimura; Kei Yamasaki; Toshinori Kawanami; Kazuhiro Yatera
Journal:  Respiration       Date:  2020-09-07       Impact factor: 3.580

2.  Scoring model of convex probe endobronchial ultrasound multimodal imaging in differentiating benign and malignant lung lesions.

Authors:  Xinxin Zhi; Lei Wang; Junxiang Chen; Xiaoxuan Zheng; Ying Li; Jiayuan Sun
Journal:  J Thorac Dis       Date:  2020-12       Impact factor: 2.895

3.  Diagnostic value of endobronchial ultrasound elastography combined with rapid onsite cytological evaluation in endobronchial ultrasound-guided transbronchial needle aspiration.

Authors:  Jing Huang; Yuan Lu; Xihua Wang; Xiaoli Zhu; Ping Li; Jing Chen; Pingsheng Chen; Ming Ding
Journal:  BMC Pulm Med       Date:  2021-12-20       Impact factor: 3.317

4.  Combination of 18F-FDG PET/CT and convex probe endobronchial ultrasound elastography for intrathoracic malignant and benign lymph nodes prediction.

Authors:  Xinxin Zhi; Xiaoyan Sun; Junxiang Chen; Lei Wang; Lin Ye; Ying Li; Wenhui Xie; Jiayuan Sun
Journal:  Front Oncol       Date:  2022-08-05       Impact factor: 5.738

5.  Automatic Image Selection Model Based on Machine Learning for Endobronchial Ultrasound Strain Elastography Videos.

Authors:  Xinxin Zhi; Jin Li; Junxiang Chen; Lei Wang; Fangfang Xie; Wenrui Dai; Jiayuan Sun; Hongkai Xiong
Journal:  Front Oncol       Date:  2021-05-31       Impact factor: 6.244

6.  Quantitative analysis of endobronchial ultrasound elastography in computed tomography-negative mediastinal and hilar lymph nodes.

Authors:  Keigo Uchimura; Kei Yamasaki; Shinji Sasada; Sachika Hara; Issei Ikushima; Yosuke Chiba; Takashi Tachiwada; Toshinori Kawanami; Kazuhiro Yatera
Journal:  Thorac Cancer       Date:  2020-07-21       Impact factor: 3.500

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.